## Emilio FÃ;brega

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8079566/publications.pdf

Version: 2024-02-01

304602 214721 2,264 47 22 47 h-index citations g-index papers 49 49 49 3452 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Antibody response to the messenger RNAâ€1273 vaccine (Moderna) in liver transplant recipients. Hepatology Communications, 2022, 6, 1673-1679.	2.0	8
2	SARS-CoV-2 and Liver Transplant: How Has It Behaved in This Sixth Wave?. Transplantation, 2022, 106, 1445-1449.	0.5	5
3	Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. Journal of Hepatology, 2021, 74, 148-155.	1.8	261
4	An Elusive Diagnosis in Noncirrhotic Chronic Portal Vein Thrombosis. American Journal of Medicine, 2021, 134, e199-e200.	0.6	1
5	Impact of the COVID-19 lockdown on liver transplant recipients. A single center observational study. Revista Espanola De Enfermedades Digestivas, 2021, , .	0.1	3
6	Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. American Journal of Transplantation, 2021, 21, 2876-2884.	2.6	32
7	Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. Scientific Reports, 2021, 11, 9819.	1.6	18
8	Number of Antibody-verified Eplet in HLA-C Locus as an Independent Factor of T-cell–Mediated Rejection After Liver Transplantation. Transplantation, 2020, 104, 562-567.	0.5	9
9	Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders. Journal of Clinical Medicine, 2020, 9, 2822.	1.0	10
10	Congestive Hepatopathy. International Journal of Molecular Sciences, 2020, 21, 9420.	1.8	37
11	Is Routine Prophylaxis Against Pneumocystis jirovecii Needed in Liver Transplantation? A Retrospective Single-Centre Experience and Current Prophylaxis Strategies in Spain. Journal of Clinical Medicine, 2020, 9, 3573.	1.0	10
12	Bone mineral density and trabecular bone score in treatment-na $\tilde{A}$ -ve patients with non-cirrhotic hepatitis C virus infection. Archives of Osteoporosis, 2020, 15, 72.	1.0	4
13	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. Digestive and Liver Disease, 2019, 51, 95-103.	0.4	12
14	Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. Journal of Clinical Medicine, 2019, 8, 1242.	1.0	5
15	FRI-373-Mismatch in C-locus Eplets between donor and recipient as independent factor of acute T-cell mediated rejection in liver transplantation. Journal of Hepatology, 2019, 70, e558-e559.	1.8	O
16	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2819-2821.	2.4	24
17	LOXL2—A New Target in Antifibrogenic Therapy?. International Journal of Molecular Sciences, 2019, 20, 1634.	1.8	50
18	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. Cells, 2019, 8, 1506.	1.8	18

#	Article	IF	CITATIONS
19	Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. World Journal of Clinical Cases, 2018, 6, 611-623.	0.3	3
20	Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil. Liver Transplantation, 2017, 23, 498-509.	1.3	51
21	Successful Continuation of HCV Treatment After Liver Transplantation. Transplantation, 2017, 101, 1009-1012.	0.5	6
22	High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation. International Immunology, 2016, 28, 55-64.	1.8	19
23	Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. Revista Espanola De Enfermedades Digestivas, 2016, 109, 17-25.	0.1	15
24	Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 1878.	1.8	28
25	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology, 2016, 233, 3947-3952.	1.5	40
26	High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients. Immunobiology, 2016, 221, 595-603.	0.8	12
27	The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. BioMed Research International, 2015, 2015, 1-8.	0.9	15
28	Plasma betatrophin levels in patients with liver cirrhosis. World Journal of Gastroenterology, 2015, 21, 10662.	1.4	17
29	Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy. Revista Espanola De Enfermedades Digestivas, 2015, 108, 421-30.	0.1	2
30	Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World Journal of Gastroenterology, 2015, 21, 11016.	1.4	35
31	Binge drinking: Burden of liver disease and beyond. World Journal of Hepatology, 2015, 7, 2703.	0.8	46
32	Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project. Hepatology, 2014, 60, 106-113.	3.6	29
33	Vitamin D deficiency in chronic liver disease. World Journal of Hepatology, 2014, 6, 901.	0.8	83
34	Etiologies and Outcomes of Acute Liver Failure in a Spanish Community. International Journal of Hepatology, 2013, 2013, 1-5.	0.4	5
35	Long-term survival after liver transplantation for alcoholic liver disease. World Journal of Gastroenterology, 2013, 19, 9198.	1.4	53
36	ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta-analysis. Liver Transplantation, 2012, 18, 1244-1252.	1.3	76

## Emilio FÃibrega

#	Article	IF	CITATIONS
37	Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transplantation, 2012, 18, 1110-1117.	1.3	28
38	Influence of aquaporin-1 gene polymorphism on water retention in liver cirrhosis. Scandinavian Journal of Gastroenterology, 2011, 46, 1267-1274.	0.6	16
39	Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transplantation, 2009, 15, 629-633.	1.3	93
40	Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized Study. Gastroenterology, 2008, 134, 1352-1359.	0.6	541
41	Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. Clinical Transplantation, 2006, 20, 383-388.	0.8	19
42	Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver International, 2005, 25, 305-310.	1.9	42
43	Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transplantation, 2005, 11, 420-426.	1.3	209
44	Liver transplantation with allografts from hepatitis B core antibody-positive donors: A new approach. Liver Transplantation, 2003, 9, 916-920.	1.3	42
45	Liver Transplantation in a Case of Steatohepatitis and Subacute Hepatic Failure after Biliopancreatic Diversion for Morbid Obesity. Obesity Surgery, 2001, 11, 640-642.	1.1	71
46	OUTCOME OF AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION1. Transplantation, 1998, 66, 1645-1650.	0.5	139
47	ENDOTHELIN-1 AND VASCULAR COMPLICATIONS IN LIVER TRANSPLANTATION. Transplantation, 1995, 59, 1748-1751.	0.5	9